Jason S. Lewis

Jason S. Lewis, PhD, is a Professor and Deputy Director at the Sloan Kettering Institute's Office of Science Education and Training (OSET), holding the Emily Tow Chair in Oncology. He leads the Jason Lewis Lab at Memorial Hospital Research Laboratories, focusing on radiopharmaceutical development for cancer diagnosis and treatment. His work bridges small- and biomolecule-based targeting agents with positron-emitting or therapeutic radioisotopes to interrogate cancer molecular profiles via noninvasive nuclear imaging and endoradiotherapy, with a strong emphasis on clinical translation.

• PhD, The University of Kent (UK)

His research spans molecular imaging, targeted radiotherapy, and theranostic agent development, with specific applications in neuroendocrine tumors, pancreatic cancer, ovarian cancer, and melanoma. Key methodologies include ImmunoPET, click chemistry, and shortwave infrared fluorescence imaging.

Recent trends in his publications (2023-2025) demonstrate expertise in:

• DLL3 (Delta-like Ligand 3) targeting for small cell lung and neuroendocrine tumors
• HER2/PD-L1 imaging in breast and gastroesophageal cancers
• Development of copper-67 and 225Ac-based theranostic agents
• Advancements in pretargeted radioimmunotherapy
• Innovations in SWIR fluorescence-guided surgery

Scientific recognition includes

• 2025 Dr. Saul Hertz Lifetime Achievement Award (SNMMI)
• 2023 Glenn T. Seaborg Award (ACS)
• 2021 Gold Medal for Lifetime Achievement (World Molecular Imaging Society)
• NCI R35 Outstanding Investigator Award (2019-2026)

The lab collaborates with multiple institutions including the Gerstner Sloan Kettering Graduate School of Biomedical Sciences, trains researchers through the Center for Molecular Imaging & Bioengineering, and maintains affiliations with Clarity Pharmaceuticals, Telix Pharmaceuticals, and pHLIP, Inc.